DBV Technologies S.A.
DBVTF- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
No open-market purchases or sales by DBV Technologies S.A. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesDBVT
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $5.64M
- +35.8% year over year
- Net income, FY2025
- -$146.9M
- −229.0% year over year
- Free cash flow, FY2025
- -$121.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.60M
- −42.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $146.9M (2607.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 358.2K
- Shares sold short
- Change
- −17.1K
- −4.6% vs. previous
- Days to cover
- 15.76
- At average daily volume
Superinvestors holding DBVTF, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DBVTF at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by DBV Technologies S.A. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 (view filing)4:15 PM ET | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −464 | $2.70 | −$1.25K | −0.3%144.5K after | |
| Feb 2, 2026 (view filing) | Jan 29 | 4 days | Mohideen PharisChief Medical Officer | SSale | −534 | $4.86 | −$2.60K | −0.4%145.0K after | |
| Dec 19, 2025 (view filing)4:04 PM ET | Dec 17-18 | 2 days | Caisse Des Depots Et Consignations and 4 othersOther: Member of 10% owner group | SSale | −3.37M | $4.60 | −$15.5M | −31.6%7.30M after | 3 lots |
| Nov 25, 2025 (view filing) | Nov 20-21 | 5 daysLate | Mohideen PharisChief Medical Officer | SSale | −8.12K | $2.86 | −$23.2K | −7.4%101.5K after | 2 lots |
| Jul 31, 2025 (view filing) | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −464 | $2.22 | −$1.03K | −0.4%109.6K after | |
| May 27, 2025 (view filing) | May 22 | 5 days | Mohideen PharisChief Medical Officer | SSale | −397 | $1.84 | −$730.48 | −0.4%110.1K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Mohideen PharisChief Medical Officer | SSale | −600 | $0.85 | −$510 | −0.5%110.5K after | |
| Nov 27, 2024 (view filing) | Nov 22-25 | 5 daysLate | Mohideen PharisChief Medical Officer | SSale | −907 | $0.5549 | −$503.31 | −0.8%111.1K after | 2 lots |
| Nov 25, 2024 (view filing) | Nov 21 | 4 days | Mohideen PharisChief Medical Officer | SSale | −2.35K | $0.54 | −$1.27K | −2.1%112.0K after | |
| Jul 31, 2024 (view filing) | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −1.78K | $0.98 | −$1.75K | −2.2%79.4K after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in DBV Technologies S.A. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding DBVTF in 13F filings for Q2 2026.